phase readout
saveNCT05925920: Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
COMPLETEDupdated 29d ago
community read0 votes
Sponsor: Metabolics Pharma. Phase: PHASE1. Conditions: Obesity, Diabetes Mellitus, Type 2
view source ↗
comments(0)
5-min edit window · permanent after that